Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Strowitzki, T.
Right arrow Articles by Bilger, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strowitzki, T.
Right arrow Articles by Bilger, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 10, No. 12, pp. 3097-3101, 1995
© 1995 European Society of Human Reproduction and Embryology

research-article

Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F) in non-down-regulated cycles

T. Strowitzki1,6, H. Kentenich2, L. Kiesel3, J. Neulen4 and W. Bilger5

1Department of Obstetrics and Gynaecology, Klinikum Gro{beta}hadern, University of Munich Marchioninistrasse 15, 81377 Munich 2Department of Obstetrics and Gynaecology, University of Berlin Charlottenburg WE14, Pulsstrasse 4, 14059 Berlin 3Department of Obstetrics and Gynaecology, University of Tubingen Schleichstrasse 4, 72076 Tubingen 4Department of Obstetrics and Gynaecology, University of Freiburg Hugstetterstrasse 55, 79106 Freiburg 5Serono Pharma Gutenbergstrasse 5, 85716 Unterschlei{beta}heim, Germany

Correspondence: 6To whom correspondence should be addressed

In order to assess the efficacy and safety of recombinant human follicle stimulating hormone (FSH) in routine clinical use, ovarian stimulation with recombinant human FSH was performed in 71 patients prior to in-vitro fertilization (IVF) without gonadotrophin-releasing hormone (GnRH) analogues in a multicentre, non-comparative study. Human chorionic gonadotrophin (HCG) was administered to 58 patients (81.7%), 15 of whom underwent 19 cycles with an initial dosage of three ampoules daily of recombinant FSH and 43 of whom underwent 152 cycles with four ampoules daily from day 3 onwards. No significant differences were detected between these two groups in all test parameters. The mean duration of treatment was 9.06 and 8.86 days respectively with a mean number of 24.06 and 23.25 vials of recombinant human FSH administered. A mean number of 6.26 and 5.88 oocytes respectively was collected. The number of transferred embryos was 2.4 and 2.2. A clinical pregnancy rate of 23.8% (10 out of 42) per transfer was achieved (30.9 and 20.6% respectively). Local tolerance of s.c. administration was excellent. Mild pain at the injection site was the dominant finding in <20% of patients. Two cases of ovarian hyperstimulation syndrome were noted. Recombinant human FSH is very attractive to patients because it can be self-administered s.c. and the preparation does not come from a human source. In conclusion, these data support the safety and efficacy of recombinant human FSH in routine use for IVF.

Key words: follicle stimulating hormone/in-vitro fertilization/ovarian stimulation/ovulation induction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
E. Lenton, A. Soltan, J. Hewitt, A. Thomson, W. Davies, N. Ashraf, V. Sharma, L. Jenner, W. Ledger, and E. McVeigh
Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP)
Hum. Reprod., May 1, 2000; 15(5): 1021 - 1027.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.